Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

Ian T Meredith; Stefan Verheye; Neil J Weissman; Paul Barragan; Douglas Scott; Mariano Valdés Chávarri; Nick E J West; Henning Kelbæk; Robert Whitbourn; Darren L Walters; Jacek Kubica; Leif Thuesen; Monica Masotti; Adrian Banning; Iwar Sjögren; Rod H Stables; Dominic J Allocco; Keith D Dawkins

doi:10.4244/EIJV9I3A52

Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

Ian T Meredith, Stefan Verheye, Neil J Weissman, Paul Barragan, Douglas Scott, Mariano Valdés Chávarri, Nick E J West, Henning Kelbæk, Robert Whitbourn, Darren L Walters, Jacek Kubica, Leif Thuesen, Monica Masotti, Adrian Banning, Iwar Sjögren, Rod H Stables, Dominic J Allocco, Keith D Dawkins

45 Citations (Scopus)

Abstract

The EVOLVE FHU trial demonstrated non-inferiority of six-month late loss with two dose formulations of SYNERGY, a novel bioabsorbable polymer everolimus-eluting stent (EES) compared with the durable polymer PROMUS Element (PE) EES. The current analysis describes the six-month IVUS and clinical results through two years from the EVOLVE FHU trial.

Original language	English
Journal	EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Volume	9
Issue number	3
Pages (from-to)	308-15
Number of pages	8
ISSN	1774-024X
DOIs	https://doi.org/10.4244/EIJV9I3A52
Publication status	Published - Jul 2013

Access to Document

10.4244/EIJV9I3A52

Cite this

Meredith, I. T., Verheye, S., Weissman, N. J., Barragan, P., Scott, D., Valdés Chávarri, M., West, N. E. J., Kelbæk, H., Whitbourn, R., Walters, D. L., Kubica, J., Thuesen, L., Masotti, M., Banning, A., Sjögren, I., Stables, R. H., Allocco, D. J., & Dawkins, K. D. (2013). Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 9(3), 308-15. https://doi.org/10.4244/EIJV9I3A52

Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. / Meredith, Ian T; Verheye, Stefan; Weissman, Neil J et al.
In: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 9, No. 3, 07.2013, p. 308-15.

Research output: Contribution to journal › Journal article › Research › peer-review

Meredith, IT, Verheye, S, Weissman, NJ, Barragan, P, Scott, D, Valdés Chávarri, M, West, NEJ, Kelbæk, H, Whitbourn, R, Walters, DL, Kubica, J, Thuesen, L, Masotti, M, Banning, A, Sjögren, I, Stables, RH, Allocco, DJ & Dawkins, KD 2013, 'Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent', EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, vol. 9, no. 3, pp. 308-15. https://doi.org/10.4244/EIJV9I3A52

Meredith IT, Verheye S, Weissman NJ, Barragan P, Scott D, Valdés Chávarri M et al. Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2013 Jul;9(3):308-15. doi: 10.4244/EIJV9I3A52

Meredith, Ian T ; Verheye, Stefan ; Weissman, Neil J et al. / Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial : a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. In: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2013 ; Vol. 9, No. 3. pp. 308-15.

@article{d70d60494be140f3ad0cb2605e56947b,

title = "Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent",

abstract = "The EVOLVE FHU trial demonstrated non-inferiority of six-month late loss with two dose formulations of SYNERGY, a novel bioabsorbable polymer everolimus-eluting stent (EES) compared with the durable polymer PROMUS Element (PE) EES. The current analysis describes the six-month IVUS and clinical results through two years from the EVOLVE FHU trial.",

author = "Meredith, \{Ian T\} and Stefan Verheye and Weissman, \{Neil J\} and Paul Barragan and Douglas Scott and \{Vald{\'e}s Ch{\'a}varri\}, Mariano and West, \{Nick E J\} and Henning Kelb{\ae}k and Robert Whitbourn and Walters, \{Darren L\} and Jacek Kubica and Leif Thuesen and Monica Masotti and Adrian Banning and Iwar Sj{\"o}gren and Stables, \{Rod H\} and Allocco, \{Dominic J\} and Dawkins, \{Keith D\}",

year = "2013",

month = jul,

doi = "10.4244/EIJV9I3A52",

language = "English",

volume = "9",

pages = "308--15",

journal = "EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology",

issn = "1774-024X",

publisher = "Europa Group",

number = "3",

}

TY - JOUR

T1 - Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial

T2 - a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

AU - Meredith, Ian T

AU - Verheye, Stefan

AU - Weissman, Neil J

AU - Barragan, Paul

AU - Scott, Douglas

AU - Valdés Chávarri, Mariano

AU - West, Nick E J

AU - Kelbæk, Henning

AU - Whitbourn, Robert

AU - Walters, Darren L

AU - Kubica, Jacek

AU - Thuesen, Leif

AU - Masotti, Monica

AU - Banning, Adrian

AU - Sjögren, Iwar

AU - Stables, Rod H

AU - Allocco, Dominic J

AU - Dawkins, Keith D

PY - 2013/7

Y1 - 2013/7

N2 - The EVOLVE FHU trial demonstrated non-inferiority of six-month late loss with two dose formulations of SYNERGY, a novel bioabsorbable polymer everolimus-eluting stent (EES) compared with the durable polymer PROMUS Element (PE) EES. The current analysis describes the six-month IVUS and clinical results through two years from the EVOLVE FHU trial.

AB - The EVOLVE FHU trial demonstrated non-inferiority of six-month late loss with two dose formulations of SYNERGY, a novel bioabsorbable polymer everolimus-eluting stent (EES) compared with the durable polymer PROMUS Element (PE) EES. The current analysis describes the six-month IVUS and clinical results through two years from the EVOLVE FHU trial.

UR - https://www.scopus.com/pages/publications/84880870416

U2 - 10.4244/EIJV9I3A52

DO - 10.4244/EIJV9I3A52

M3 - Journal article

C2 - 23872647

SN - 1774-024X

VL - 9

SP - 308

EP - 315

JO - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

JF - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

IS - 3

ER -

Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

Abstract

Access to Document

Other files and links

Fingerprint

Cite this